These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 31952272)
1. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights. Anestis A; Zoi I; Papavassiliou AG; Karamouzis MV Molecules; 2020 Jan; 25(2):. PubMed ID: 31952272 [TBL] [Abstract][Full Text] [Related]
2. Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes. Shukla N; Shah K; Rathore D; Soni K; Shah J; Vora H; Dave H Life Sci; 2024 Jul; 348():122697. PubMed ID: 38710280 [TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631 [TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review. Jahan N; Jones C; Rahman RL Mol Cell Endocrinol; 2021 Jul; 531():111324. PubMed ID: 34000352 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer. Salvi S; Bonafè M; Bravaccini S Semin Cancer Biol; 2020 Feb; 60():132-137. PubMed ID: 31002873 [TBL] [Abstract][Full Text] [Related]
6. The Role of the Androgen Receptor Signaling in Breast Malignancies. Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427 [TBL] [Abstract][Full Text] [Related]
7. Consideration of breast cancer subtype in targeting the androgen receptor. Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689 [TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor in Breast Cancer: From Bench to Bedside. Chen M; Yang Y; Xu K; Li L; Huang J; Qiu F Front Endocrinol (Lausanne); 2020; 11():573. PubMed ID: 32982970 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor signaling pathways as a target for breast cancer treatment. Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625 [TBL] [Abstract][Full Text] [Related]
10. The role of the androgen receptor in triple-negative breast cancer. Shah PD; Gucalp A; Traina TA Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA; Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901 [TBL] [Abstract][Full Text] [Related]
12. Targeting the androgen receptor in triple-negative breast cancer. Gucalp A; Traina TA Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor: A promising therapeutic target in breast cancer. Vasiliou SK; Diamandis EP Crit Rev Clin Lab Sci; 2019 May; 56(3):200-223. PubMed ID: 30821186 [TBL] [Abstract][Full Text] [Related]
14. Role of the androgen receptor in triple-negative breast cancer. Rampurwala M; Wisinski KB; O'Regan R Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032 [TBL] [Abstract][Full Text] [Related]
15. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907 [TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648 [TBL] [Abstract][Full Text] [Related]
17. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Naderi A; Chia KM; Liu J Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548 [TBL] [Abstract][Full Text] [Related]
18. The Androgen Receptor: Is It a Promising Target? Gucalp A; Traina TA Ann Surg Oncol; 2017 Oct; 24(10):2876-2880. PubMed ID: 28766215 [TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: role of the androgen receptor. Gucalp A; Traina TA Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692 [TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. You CP; Leung MH; Tsang WC; Khoo US; Tsoi H Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]